Background: Cyclooxygenase (COX) is a rate limiting enzyme in synthesis of prostanoids pathway and it has 2 isoforms (COX-1 and COX-2). It has many biological roles in inflammation and oncogenesis. Cox-2 was incriminated in performing disturbances in the cell cycle control in CRC, but its role of in CRC needs clarification of the mechanisms by which Cox-2 might affect the process of colorectal carcinogenesis. Cyclin D1 is an oncogene that regulates G1 phase progression to S phase of the cell cycle. Its stimulatory role on cell cycle is antagonized by Cyclin D1-dependent kinase (CDK) inhibitors like p21. P21 plays an essential role in cell cycle regulation; it may have a pro-apoptotic or an antiapoptotic role in cancer. P21 was found to have many roles in cancer; invasion metastases, cellular senescence and stem cells aging. The roles of combined expression of Cox-2, Cyclin D1 and P21 in CRC tissues and their role of prognosis and patients survival are not sufficiently clarified. Aim of the Study: To evaluate tissue expression of Cox-2, Cyclin D1 and P21 in CRC and to correlate such expression with pathological parameters, clinical and prognostic data of the patients. Methods: Cox-2, Cyclin D1 and P21 are evaluated in colon cancer tissues. Correlations between their level of expressions pathological parameters, clinical and prognostic data of patients were analyzed. Results: Cox-2, Cyclin D1 over-expression was associated with higher grade, higher incidence of occurrence of lymph node & distant metastasis and advanced stage (P = 0.000). Cox-2 was related to higher tumor recurrence rate (P = 0.04) and decreased overall patients survival rate (p = 0.002). (r correlation coefficient = +0.987). Conclusion: Cox-2 and Cyclin D1 are markers of poor prognosis colon cancer patients.
References
[1]
Favoriti, P., Carbone, G., Greco, M., et al. (2016) Worldwide Burden of Colorectal Cancer: A Review. Updates in Surgery, 68, 7-11.
https://doi.org/10.1007/s13304-016-0359-y
[2]
Rafiemanesh, H., Pakzad, R., Abedi, M., et al. (2016) Colorectal Cancer in Iran: Epidemiology and Morphology Trends. EXCLI Journal, 15, 738-744.
[3]
Wood, L.D., Parsons, D.W., Jones, S., et al. (2007) The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 318, 1108-1113.
https://doi.org/10.1126/science.1145720
[4]
Elzagheid, A., Emaetigi, F., Lamia Alkikhia, L., et al. (2013) High Cyclooxygenase-2 Expression Is Associated with Advanced Stages in Colorectal Cancer. Anticancer Research, 33, 3137-3144.
[5]
Li, Y., Wei, J., Xu, C., et al. (2014) Prognostic Significance of Cyclin D1 Expression in Colorectal Cancer: A Meta-Analysis of Observational Studies. PLOS ONE, 9, e94508. https://doi.org/10.1371/journal.pone.0094508
[6]
Cao, J., Einstein, M., Anderson, P., et al. (2002) Expression of COX-2, Ki-67, Cyclin D1, and P21 in Endometrial Endometrioid Carcinomas. International Journal of Gynecological Pathology, 21, 147-154.
https://doi.org/10.1097/00004347-200204000-00007
[7]
Peng, L., Zhou, Y., Wang, Y., et al. (2013) Prognostic Significance of COX-2 Immunohistochemical Expression in Colorectal Cancer: A Meta-Analysis of the Literature. PLOS ONE, 8, e58891.
[8]
Wu, W.K., Sung, J.J., Lee, C.W., et al. (2010) Cyclooxygenase-2 in Tumorigenesis of Gastrointestinal Cancers: An Update on the Molecular Mechanisms. Cancer Letters, 295, 7-16. https://doi.org/10.1016/j.canlet.2010.03.015
[9]
Tatsuguchi, A., Kishida, T., Fujimori, S., et al. (2006) Differential Expression of Cyclo-Oxygenase-2 and Nuclear B-Catenin in Colorectal Cancer Tissue. Alimentary Pharmacology & Therapeutics, 24, 153-159.
https://doi.org/10.1111/j.1365-2036.2006.00039.x
[10]
Jiang, H., Wang, J. and Zhao, W. (2013) Cox-2 in Non-Small Cell Lung Cancer: A Meta-Analysis. Clinica Chimica Acta, 419, 26-32.
https://doi.org/10.1016/j.cca.2013.01.012
[11]
Song, J., Su, H., Zhou, Y., et al. (2014) Cyclooxygenase-2 Expression Is Associated with Poor Overall Survival of Patients with Gastric Cancer: A Meta-Analysis. Digestive Diseases and Sciences, 59, 436-445. https://doi.org/10.1007/s10620-013-2917-1
[12]
Theocharis, S., Giaginis, C., Parasi, A., et al. (2007) Expression of Peroxisome Proliferator-Activated Receptor-γ in Colon Cancer: Correlation with Histopathological Parameters, Cell Cycle-Related Molecules, and Patients’ Survival. Digestive Diseases and Sciences, 52, 2305-2311. https://doi.org/10.1007/s10620-007-9794-4
[13]
Besson, A., Dowdy, S.F. and Roberts, J.M. (2008) CDK Inhibitors: Cell Cycle Regulators and Beyond. Developmental Cell, 14, 159-169.
https://doi.org/10.1016/j.devcel.2008.01.013
[14]
Van Wangenheim, C., Monig, S., Schneider, P., et al. (2008) p16, Cyclin D1 and Rb Expression in Colorectal Carcinomas: Correlations with Clinico-Pathological Parameters and Prognosis. Molecular Medicine Reports, 1, 27-32.
[15]
Ogino, S., Nosho, K., Irahara, N., et al. (2009) A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases. Clinical Cancer Research, 15, 4431-4438. https://doi.org/10.1158/1078-0432.CCR-08-3330
[16]
Abukhdeir, A.M. and Park, B.H. (2008) P21 and p27 Roles in Carcinogenesis and Drug Resistance. Expert Reviews in Molecular Medicine, 10, e19.
https://doi.org/10.1017/S1462399408000744
[17]
Hsu, S.M., Raine, L. and Fanger, H. (1981) Use of Avidin-Biotin-Peroxidase Complex (ABC) in Immunoperoxidase Techniques: A Comparison between ABC and Unlabeled Antibody (PAP) Procedures. Journal of Histochemistry & Cytochemistry, 29, 577-580. https://doi.org/10.1177/29.4.6166661
[18]
Bagir, E.K., Açikalin, A., Izol, V., Seydaoglu, G. and Erdogan, S. (2016) Immuno-histochemical Study of Cyclooxygenase-2 Expression in Prostate Carcinoma: It's Relation with Apoptosis and Angiogenesis. Bulletin of Urooncology, 15, 144-147.
[19]
Lee, J.Y., Myung, S.K. and Song, Y.S. (2013) Prognostic Role of Cyclooxygenase-2 in Epithelial Ovarian Cancer: A Meta-Analysis of Observational Studies. Gynecologic Oncology, 129, 613-619. https://doi.org/10.1016/j.ygyno.2013.02.011
[20]
Wu, A.W., Gu, J., Ji, J.F., Li, Z.F. and Xu, G.W. (1990) Role of COX2 in Carcinogenesis of Colorectal Cancer and Its Relationship with Tumor Biological Characteristics and Patients’ Prognosis. World Journal of Gastroenterology, 9, 1990-1994.
[21]
Al-Maghrabi, J., Buhmeida, A., Emam, E., et al. (2012) Cyclooxygenase-2 Expression as a Predictor of Outcome in Colorectal Carcinoma. World Journal of Gastroenterology, 18, 1793-1799. https://doi.org/10.3748/wjg.v18.i15.1793
[22]
Miladi-Abdennadher, I., Abdelmaksoud-Dammak, R., Ayed-Guerfali, D.B., et al. (2012) Expression of COX2 and E-Cadherin in Tunisian Patients with Colorectal Adenocarcinoma. Acta Histochemica, 114, 577-581.
https://doi.org/10.1016/j.acthis.2011.11.002
[23]
Lim, S.C., Cho, H., Lee, T.B., et al. (2010) Impacts of Cytosolic Phospholipase A2, 15-Prostaglandin Dehydrogenase, and Cyclooxygenase-2 Expressions on Tumor Progression in Colorectal Cancer. Yonsei Medical Journal, 51, 692-699.
https://doi.org/10.3349/ymj.2010.51.5.692
[24]
Holland, T.A., Elder, J., McCloud, J.M., et al. (2001) Subcellular Localisation of Cyclin D1 Protein in Colorectal Tumours Is Associated with p21 (WAF1/CIP1) Expression and Correlates with Patient Survival. International Journal of Cancer, 95, 302-306.
https://doi.org/10.1002/1097-0215(20010920)95:5<302::AID-IJC1052>3.0.CO;2-#
[25]
Wong, N.A., Morris, R.G., McCondochie, A., et al. (2002) Cyclin D1 Overexpression in Colorectal Carcinoma in Vivo Is Dependent on Beta-Catenin Protein Dysregulation, But Not k-Ras Mutation. The Journal of Pathology, 197, 128-135.
https://doi.org/10.1002/path.1113
[26]
McKay, J.A., Douglas, J.J., Ross, V.G., et al. (2002) Analysis of Key Cell-Cycle Checkpoint Proteins in Colorectal Tumours. The Journal of Pathology, 196, 386-393. https://doi.org/10.1002/path.1053
[27]
Wangefjord, S., Manjer, J., Gaber, A., et al. (2010) Cyclin D1 Expression in Colorectal Cancer Is a Favorable Prognostic Factor in Men But Not in Women in a Prospective, Population-Based Cohort Study. Biology of Sex Differences, 2, 10.
http://www.bsd-journal.com/content/2/1/10
[28]
Bahnassy, A.A., Zekri, A.R., El-Houssini, S., et al. (2004) Cyclin A and Cyclin D1 as Significant Prognostic Markers in Colorectal Cancer Patients. BMC Gastroenterology, 4, 22. https://doi.org/10.1186/1471-230X-4-22
[29]
Maeda, K., Chung, Y.S., Kang, S.M., et al. (1997) Overexpression of Cyclin D1 and p53 Associated with Disease Recurrence in Colorectal Adenocarcinoma. International Journal of Cancer, 74, 310-315.
https://doi.org/10.1002/(SICI)1097-0215(19970620)74:3<310::AID-IJC13>3.0.CO;2-F
[30]
Lehn, S., Tobin, N.P., Berglund, P., et al. (2010) Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic Features. American Journal of Pathology, 177, 2886-2897.
https://doi.org/10.2353/ajpath.2010.100303
[31]
Pavey, S., Zuidervaart, W., van Nieuwpoort, F., et al. (2006) Increased p21-Activated Kinase-1 Expression Is Associated with Invasive Potential in Uveal Melanoma. Melanoma Research, 16, 285-296. https://doi.org/10.1097/01.cmr.0000222589.30117.f2
[32]
He, H. and Baldwin, G.S. (2008) GTPases and p21-Activated Kinase in the Regulation of Proliferation and Apoptosis by Gastrins. The International Journal of Biochemistry & Cell Biology, 40, 2018-2022.
https://doi.org/10.1016/j.biocel.2008.05.002
[33]
Esposito, V., Baldi, A., Tonini, G., et al. (2004) Analysis of Cell Cycle Regulator Proteins in Non-Small Cell Lung Cancer. Journal of Clinical Pathology, 57, 58-63.
https://doi.org/10.1136/jcp.57.1.58
